Massachusetts General Hospital Corporate & Foundation Relations Office of Development
PRIVATE FUNDING OPPORTUNITIES: SEP 21, 2018 Please contact Corporate & Foundation Relations in the Office of Development at [email protected] if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.
Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.
1. IDEA Grants, Barth Syndrome Foundation, Inc. (BSF) The Barth Syndrome Foundation, Inc. (BSF) and its international affiliates announce the availability of funding for basic science and clinical research on the natural history, biochemical basis, and treatment of Barth syndrome.
Barth syndrome (BTHS) is a serious X-linked genetic condition associated with cardiomyopathy, neutropenia, skeletal muscle weakness, exercise intolerance, growth delay, and diverse biochemical abnormalities (including defects in mitochondrial metabolism and phospholipid biosynthesis). Because many clinical and biochemical abnormalities of Barth syndrome remain poorly understood, we are seeking proposals for both basic science and clinical research that may shed light on any aspect of the syndrome with the object of developing a specific treatment or a cure.
We are interested in providing "seed grant funding" to young investigators as well as attracting experienced investigators new to the field of Barth syndrome basic science or clinical research. We anticipate that these funds will be used for the testing of initial hypotheses and the collection of preliminary data leading to successful long-term funding by the National Institutes of Health (NIH) and other major granting institutions around the world.
BSF's Research Grant Program now requires all applicants to be independent investigators (e.g., faculty appointment). Postdoctoral fellows cannot apply.
Citizenship: Unrestricted
Do you want to learn more about identifying external funding opportunities? See ECOR’s website for information on the funding opps database, COS Pivot or contact Amy Robb
2. Career Development Awards, Crohn's and Colitis Foundation of America, Inc. (CCFA) The objective of the Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of inflammatory bowel disease (IBD).
Proposal MUST be relevant to IBD (Crohn's disease and/or ulcerative colitis) and must contain a career development plan detailing a training plan, mentorship plan, and describe how receiving this award will facilitate the transition to independence. Only one application is allowed per applicant per submission date. Simultaneous submission of a Senior Research Award and Training Award is not permitted.
Citizenship: Unrestricted
Award Amount: $90,000-$270,000 paid over 1-3 years Indirect Costs: None LOI Deadline: Nov 5, 2018 Full Proposal Deadline: Jan 28, 2019 Website: http://www.crohnscolitisfoundation.org/science-and-professionals/research/grants- fellowships/career-development-awards.html
3. Ted and Elaine Welp Enhanced Career Development Award in Inherited Orphan Retinal Degenerative Diseases, Foundation Fighting Blindness (FFB) The Foundation Fighting Blindness (FFB) and the Foundation Fighting Blindness-Clinical Research Institute (FFB-CRI) are dedicated to supporting research to advance therapeutic and preventive strategies for inherited orphan retinal degenerative diseases into the clinic.
This program for enhanced research and clinical training is intended to support a strong pool of clinician-scientists with a commitment to clinical research on inherited orphan retinal degenerative diseases by providing support for: • the recruitment of clinician-scientists whose research focus in iRDs has been for five or fewer years, or • the retention of early-career clinician-scientists with prior career development support (K-type or other CDA) who have not secured support as Principal Investigator for independent research (e.g. R01 or Individual Investigator award).
Citizenship: Unrestricted
CFR Funding Opps | Page 2 Award Amount: $510,000 paid over 3 years Indirect Costs: None Application Deadline: Oct 31, 2018 Website: https://www.blindness.org/apply-for-funding
4. Program Project Award (PPA), Foundation Fighting Blindness (FFB) New The PPA is designed to support collaborative, multi-disciplinary, research studies that engage investigators with different expertise and resources. The PPA is intended to enable studies that are too large or complex for a single investigator to undertake in a reasonable amount of time and to address gaps in our current knowledge or therapeutic options. The PPA must be unified around a single, well-articulated hypothesis and a clearly defined deliverable(s), relevant to the mission of FFB. The teams supported by a PPA must be tightly integrated and sharply focused, freely share data and creative ideas, and each be essential to the common goal.
The PPA is not intended to support clinical research unless it is tightly integrated with the other projects and the PPA is not intended to support research cores.
The PPA must address a knowledge gap or therapeutic goal identified by the FFB SAB, or an equally significant gap or goal approved by the FFB prior to submission of the PPA proposal. When addressing a therapeutic, the teams should consider the practicalities of the intended clinical use of the deliverable, including which disease it may be intended to treat, formulation, delivery, and dosing, and to the extent possible, the research plan should be designed around the intended clinical use of the therapeutic.
Inherited retinal degeneration diseases that the research will impact may include Retinitis Pigmentosa, Bardet-Biedl, Bestrophin Disease, Blue-cone Monochromacy, Cone-Rod Dystrophy, Choroideremia, dry Age-related Macular Degeneration, Leber Congenital Amaurosis, Refsum, Retinoschisis, Stargardt, and Usher Syndrome.
Citizenship: Unrestricted
Award Amount: Unspecified Indirect Costs: Unspecified LOI Deadline: Nov 1, 2018 (Invited) Full Proposal Deadline: Feb 11, 2019 Website: https://www.blindness.org/apply-for-funding
CFR Funding Opps | Page 3 5. Diana Davis Spencer Clinical/Research Fellowship Award Program in Inherited Orphan Retinal Degenerations, Foundation Fighting Blindness (FFB) The Foundation is soliciting applications from individuals with a demonstrated interest in inherited orphan retinal degenerations. The program will provide funding for post-residency clinical fellowships in inherited orphan retinal degenerations.
The goal of this program is to increase the number of clinician- scientists with expertise and commitment to provide clinical care to patients with inherited orphan retinal degenerations. With this goal in mind, the program is also designed to prepare fellows for careers in academic medicine, providing critical training in an environment that fosters research to develop preventions, treatments, and cures for inherited orphan retinal degenerations.
Fellowships must include a significant clinical or basic research component. Ideal mentors should therefore be clinicians/clinician-scientists/scientists who have an established clinical practice in inherited orphan retinal degenerations and an established research program. Scientists with an established research program can serve as a co-mentor with a practicing clinician. Mentoring for the clinical and research components of the fellowship can be provided by a single individual or a team of mentors.
Citizenship: Unrestricted
Award Amount: $65,000 for 1 year Indirect Costs: None Application Deadline: Oct 1, 2018 Website: https://www.blindness.org/apply-for-funding
6. Gilead Sciences Research Scholars Cardiovascular Comorbidities Program, Gilead Sciences, Inc./Gilead Sciences Pty Ltd The program is designed to support basic and clinical research in the fields of cardiovascular disease or pulmonary arterial hypertension and one of the following areas: HIV, liver disease, rheumatic autoimmune disease, or inflammatory bowel disease.
Citizenship: United States
Award Amount: $130,000 paid over 2 years Indirect Costs: 10% Application Deadline: Dec 14, 2018 Website: http://researchscholars.gilead.com/en/cardiovascular_disease_portal
CFR Funding Opps | Page 4 7. Grants Program for Myelodysplastic Syndromes (MDS) Research, Health Resources in Action (HRiA)/The Medical Foundation The Taub Foundation Grants Program for Myelodysplastic Syndromes (MDS) Research was created to support high-impact, innovative translational research to understand the underlying causes of MDS and to advance its treatment and prevention. The Program specifically focuses on MDS research, exclusive of AML and MPN. Studies focusing on molecular genetics, epigenetics, splicing factors, stem cells, the microenvironment and novel therapeutic targets relevant to MDS are encouraged.
Innovative studies with transformative potential to elucidate MDS etiology and to develop new treatments are particularly encouraged.
The Taub Program supports independent investigators at all stages of their careers. To promote the expansion of the MDS research field collaborative efforts and proposals from young investigators and those from non-MDS fields are encouraged to apply.
Citizenship: Unrestricted
Award Amount: $600,000 paid over 3 years Indirect Costs: 10% Application Deadline: Nov 8, 2018 Website: https://hria.org/tmf/taub/
8. Demonstrating the Power of Evidence-Based Programs to "Move the Needle" on Major U.S. Social Problems, Laura and John Arnold Foundation (LJAF) A central goal of U.S. evidence-based policy reform is to focus government and philanthropic funding on social programs and practices ("interventions") that have credible evidence of meaningful positive effects on people's lives. The imperative for doing so is clear: Most social interventions are unfortunately found not to produce the hoped-for effects when rigorously evaluated - a pattern that occurs not just in social spending but in other fields, such as medicine and business. Thus, without a strong focus on evidence-based interventions, it is hard to see how social spending can successfully address poverty, educational failure, violence, drug abuse, and other critical U.S. problems.
Fortunately, there are some social interventions that have been rigorously shown to improve important life outcomes. While relatively few in number, their strong evidence of sizable effects suggests that, if expanded, they offer a path to meaningful progress that spending-as-usual cannot.
The Laura and John Arnold Foundation's (LJAF) Moving the Needle initiative seeks to spur expanded implementation of such interventions in order to make significant headway against
CFR Funding Opps | Page 5 U.S. social problems. Specifically, the initiative is designed to encourage state or local jurisdictions, or other entities, to: 1. Adopt social interventions shown in well-conducted randomized controlled trials (RCTs) to produce large, sustained effects on important life outcomes; 2. Implement these interventions on a sizable scale with close adherence to their key features; and 3. Determine, through a replication RCT, whether the large effects found in prior research are successfully reproduced so as to move the needle on important social problems.
Citizenship: United States
Award Amount: $1 million-$5 million Indirect Costs: 20% LOI Deadline: Continuous Website: http://www.arnoldfoundation.org/request-for-proposals/
9. Randomized Controlled Trials to Evaluate Social Programs Whose Delivery Will Be Funded by Government or Other Entities, Laura and John Arnold Foundation (LJAF) The Foundation's Evidence-Based Policy team invites grant applications to conduct randomized controlled trials (RCTs) of social programs in any area of domestic policy in which: i. LJAF will fund the RCT, and government or an other entity will fund the program 's delivery; and ii. The RCT meets the additional selection criteria set out below.
The goal in funding such RCTs is to build the body of programs rigorously shown to produce sizable, sustained benefits to participants or society, and to do so in a cost-efficient manner by leveraging program funds contributed by government, philanthropic foundations, or other funders.
The selection criteria in this request for proposals (RFP) are similar to those in LJAF's RFP for low-cost RCTs. Specifically, the Foundation seeks to fund sizable RCTs with strong designs that evaluate programs with highly promising prior evidence or that are widely implemented, and the RCTs must measure outcomes of self-evident policy importance over a sustained period of time.
Citizenship: United States
Award Amount: Unspecified Indirect Costs: 20% LOI Deadline: Continuous Website: http://www.arnoldfoundation.org/request-for-proposals/
CFR Funding Opps | Page 6 10. Pilot Study Awards, Marsha Rivkin Center for Ovarian Cancer Research Funding for innovative approaches to scientific questions can be difficult to find as these new ideas may not yet be mainstream in the scientific community. In order to foster these novel ideas the Rivkin Center for Ovarian Cancer funds promising pilot studies in ovarian cancer each year. The discoveries from these studies lay the groundwork for major research initiatives and allow scientists to further pursue research ideas through highly competitive national government grants necessary to complete these projects. Funding is open to investigator- initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered.
Citizenship: Unrestricted
Award Amount: $75,000 for 1 year Indirect Costs: None Application Deadline: Dec 3, 2018 Website: https://www.rivkin.org/research/apply/
11. Research Grant Program, Mendez National Institute of Transplantation Foundation The Mendez National Institute of Transplantation Foundation (MNITF) is a public non-profit organization that adheres to its mission of advancing the science and practice of organ transplantation and end-stage organ disease therapies through research, education, and innovation. Building upon the vision and legacy of our founders, Doctors Robert and Rafael Mendez, the MNITF awards grants semiannually to researchers through our Research Grant Program (RGP), in order to improve clinical outcomes and positively impact the field of transplantation. We plan to achieve this by: • Creating a comprehensive, multi-disciplinary program of research that advances scientific knowledge which will improve clinical outcomes in transplantation; • Integrating the field of transplantation with the latest donor screening technologies, immunogenetics, post-transplant monitoring, and advancements in regenerative medicine; • Making unique contributions to biology and medicine by developing new diagnostic and therapeutic paradigms; • Empowering patients with end-stage organ disease and transplant recipients through education to proactively manage their health and improve their long-term outcomes.
Citizenship: Unrestricted
Award Amount: $50,000-$150,000 for 1 year Indirect Costs: 10% LOI Deadline: Nov 1, 2018 (Invited) Proposal Deadline: Dec 15, 2018 Website: http://www.mnitf.org/research-funding/
CFR Funding Opps | Page 7 12. RISK Award, Munich Re Foundation The RISK Award will be assigned to an operational project in the field of the specific biennial topic. The risks must be related to natural, climate change and or/environmental issues. Risks due to social turmoil, war, chemical disasters, and/or political crises cannot be funded.
For the 2019 RISK Award, the proposal must address: "Coastal Resilience".
The proposed project must include an implementation part (action), a proposal solely based on research is not sufficient.
Citizenship: Unrestricted
Award Amount: Up to €100,000 EUR paid over 6-12 months Indirect Costs: Unspecified Proposal Deadline: Nov 30, 2018 Website: https://event.munichre- foundation.org/tms/abstractFrontend/index.cfm?l=1843&sp_id=2
13. Catalyst Grant, Pancreatic Cancer Action Network (PANCAN) Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field. Proposed research may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.
Citizenship: United States
Award Amount: $500,000 paid over 3 years Indirect Costs: 10% Application Deadline: Dec 7, 2018 Website: https://www.pancan.org/research/grants-program/apply-for-a-pancreatic-cancer- research-grant/
14. Translational Research Grant, Pancreatic Cancer Action Network (PANCAN) The 2019 Pancreatic Cancer Action Network Translational Research Grant will fund high priority pancreatic cancer research that is poised for important translational next steps to help move scientific discovery to application in patients. The Pancreatic Cancer Action Network has partnered with the Celgene Corporation to accelerate the development of novel therapies by establishing strong relationships between academia and industry through research grants. Funded projects will benefit from industry input and insight, leading to an accelerated translation into a therapeutic product.
CFR Funding Opps | Page 8 To be eligible for a Translational Research Grant, the research project should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Of particular interest are research projects that fall into at least one of these three areas of research: a) Immune context and tumor microenvironment interactions, b) Regulators of pathogenesis, progression and metabolism, with particular interest in epigenetic mechanisms and c) Transcriptional networks essential for viability and maintenance of malignant phenotype.
Citizenship: United States
Award Amount: $500,000 paid over 2 years Indirect Costs: 10% Application Deadline: Dec 21, 2018 Website: https://www.pancan.org/research-grants-program/apply-for-a-pancreatic-cancer- research-grant/
15. Clinical and Translational Pharmacology - Faculty Development Award, Pharmaceutical Research and Manufacturers of America Foundation, Inc. (PhRMA Foundation) This award identifies and supports clinical and basic scientists pursuing careers in clinical and translational pharmacology and encourages the development of junior research-oriented faculty who will use molecular, cellular, and systems pharmacology to advance human research with a focus on application to real world clinical issues.
This award seeks to support the development of faculty who, through training and experience, are committed to incorporating both the bench-to-bedside and bedside-to-bench perspectives within their research programs and mentoring of students and fellows. The program's goal is to help close the gap between medical practice and more fundamental science by supporting such critical research and the dissemination of its results through publication and development of new training programs.
Clinical pharmacology is the science of developing and using drugs for the treatment of disease in people. It is underpinned by the basic science of pharmacology, with added focus on the application of pharmacological principles and methods in the real world. It has a broad scope, from the discovery of new target molecules for use in humans to the effects of drug use in populations.
Translational pharmacology encompasses the many complexities affecting patients and as medicine is actually practiced, including co-morbidities, polypharmacy, poor adherence, genomic differences, and other factors, e.g., off-label prescribing and non-compliance with clinical guidelines at the individual and population levels.
CFR Funding Opps | Page 9 The clinical-translational pharmacologist promotes safe prescribing, maximizing beneficial drug effects while minimizing adverse effects. Those who are part of this profession understand the impact of a patient's clinical history, lifestyle, physical and cultural environment and genomic profile, as well as the "standard of care" and its relationship to existing clinical guidelines and current research results.
Clinical-translational pharmacologists may be initially trained as either basic or clinical scientists and have often enhanced this training with additional classes or research in alternative domains and through interdisciplinary collaborations. Training should be adequate to enable the rigorous evaluation and production of new data through well-designed studies involving human subjects. Among responsibilities to patients and to treating physicians are the analysis of adverse drug effects, therapeutic efficacy, toxicology (including reproductive toxicology), cardiovascular risks, perioperative drug management, and psychopharmacology.
Citizenship: United States
Award Amount: $240,000 paid over 2 years Indirect Costs: 8% Application Deadline: Feb 1, 2019 Website: http://www.phrmafoundation.org/2018-awards/other-awards/clinical- pharmacology/faculty-development-award/
16. Post Doctoral Fellowships - Health Outcomes, Pharmaceutical Research and Manufacturers of America Foundation, Inc. (PhRMA Foundation) This award supports individuals engaged in a research training program that will extend their credentials in health outcomes.
Health Outcomes research spans a broad spectrum of issues related to health-care delivery, from studies evaluating effectiveness of a pharmaceutical intervention, to the impact of reimbursement policies on outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of ways in which results of outcomes research are disseminated to providers or consumers to encourage behavior change.
Outcomes research incorporates a variety of methods from different disciplines. The application of outcomes research principles in evaluating the design, delivery, and effectiveness of pharmaceuticals includes but isn't limited to the following general areas:
Pharmacoeconomics Pharmacoeconomics evaluates behavior of individuals, organizations, and markets concerning use of pharmaceutical products, services, and programs. The discipline frequently focuses on costs (inputs) and consequences (outcomes) of pharmaceutical use.
CFR Funding Opps | Page 10 Patient Reported Outcomes Patient Reported Outcomes focuses on the value assigned to duration of life as modified by the impairment of physical, social, and psychological functional states, perceptions, and opportunities influenced by disease, injury, treatment, or policy. In this context, the field is also known as health-related quality of life.
Citizenship: United States
Award Amount: $55,000-$110,000 paid over 1-2 years Indirect Costs: None Application Deadline: Feb 1, 2019 Website: http://www.phrmafoundation.org/2018-awards/post-doctoral-fellowships/health- outcomes/
17. E.W. "Al" Thrasher Awards, Thrasher Research Fund The Thrasher Research Fund has been awarding grants for children's medical research for over 40 years. The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on€< projects that have the potential to translate into clinically meaningful results within a few years.
The Thrasher Research Fund is open to applications that address a variety of significant pediatric problems. Both incidence and severity are considered when determining the significance of the proposed topic.
Ideal applications for the E.W. "Al" Thrasher Award address significant health problems that affect children in large numbers and offer the potential for practical solutions to these problems. Such solutions should be innovative and have the potential for broad applicability with low financial and/or technical barriers to implementation. Hypothesis-driven research is preferred over exploratory, hypothesis-generating research. Projects with a shorter distance to clinical applicability are given priority.
Citizenship: Unrestricted
Award Amount: Unspecified award amount for 3 year projects. (In 2012-2016 the median grant was $320,000). Indirect Costs: 7% Concept Paper/Proposal Deadline: Continuous Website: https://www.thrasherresearch.org/al-thrasher-award?lang=eng
CFR Funding Opps | Page 11